Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bronchiectasis Clear all
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

NCT00669331
View directory record Official record
Conditions
Bronchiectasis
Interventions
Inhaled mannitol, Matched control
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years to 85 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
19
States / cities
Denver, Colorado • Farmington, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 4, 2026, 1:02 PM EDT
Terminated Not applicable Interventional

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 4, 2026, 1:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Bronchiectasis

NCT00943514
View directory record Official record
Conditions
Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 1:02 PM EDT
Completed No phase listed Observational

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

NCT04702243
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome
Interventions
Genetic Testing for PCD or PID, Unaffected Family Member Genetic Testing
Diagnostic Test · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 45 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 4, 2026, 1:02 PM EDT
Suspended Phase 2 Interventional

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

NCT07547436
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
SAR445399, Placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Loxahatchee Groves, Florida • Plantation, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life

NCT05523180
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
ResBiotic Nutrition, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • The Villages, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Phase 4 Interventional

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

NCT05743946
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Trikafta
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

NCT05865886
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
BI 1291583, Placebo to BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Denver, Colorado • Altamonte Springs, Florida • South Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 4, 2026, 1:02 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

NCT05006573
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Benralizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 4, 2026, 1:02 PM EDT
Completed No phase listed Observational

Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia

NCT05161858
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, Kartagener Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 4, 2026, 1:02 PM EDT
Completed No phase listed Observational

A Study of Home-based Pulmonary Rehabilitation and Health Coaching to Treat Bronchiectasis

NCT05553119
View directory record Official record
Conditions
Bronchiectasis
Interventions
Home Rehabilitation Monitoring System, Health coaching calls
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 4, 2026, 1:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Lung Ultrasound Artefact Analysis for Exclusion of Acute Rejection in Lung Transplant Recipients

NCT04582279
View directory record Official record
Conditions
Post-Lung Transplantation Bronchiectasis
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Not applicable Interventional

Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis

NCT06164470
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Support Group
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Not applicable Interventional

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

NCT02661438
View directory record Official record
Conditions
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Interventions
Placebo to Ciprofloxacin DPI (BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Vero Beach, Florida • Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 4, 2026, 1:02 PM EDT
Completed No phase listed Observational

Rare Genetic Disorders of the Breathing Airways

NCT00323167
View directory record Official record
Conditions
Kartagener Syndrome, Cystic Fibrosis, Pseudohypoaldosteronism, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
7
States / cities
Palo Alto, California • Denver, Colorado • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 4, 2026, 1:02 PM EDT
Completed No phase listed Observational

Cross-sectional Characterization of Idiopathic Bronchiectasis

NCT01264055
View directory record Official record
Conditions
Infection, Bronchial Diseases, Respiratory Tract Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
5
States / cities
Stanford, California • Denver, Colorado • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 4, 2026, 1:02 PM EDT
Recruiting Phase 3 Interventional

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892
View directory record Official record
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo matching BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 1:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

COPD Patient-Powered Research Network

NCT02803242
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder, Chronic Obstructive Lung Disease, Emphysema, Chronic Bronchitis
Interventions
Patient Reported Outcomes
Other
Lead sponsor
COPD Foundation
Other
Eligibility
18 Years and older
Enrollment
75,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2030
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 4, 2026, 1:02 PM EDT
Not listed Not applicable Interventional

Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

NCT06304207
View directory record Official record
Conditions
Copd, COPD Exacerbation, COPD Bronchitis, Emphysema or COPD, Chronic Lung Disease, Pulmonary Fibrosis, Interstitial Lung Disease, Bronchiectasis, Chronic Asthma, Chronic Asthmatic Bronchitis
Interventions
Onsite Maintenance Exercise Training, Telehealth Maintenance Exercise
Combination Product
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements

NCT03534986
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
International Biophysics AffloVest, Hill-Rom The Vest, Respirtech inCourage, Electromed SmartVest
Device
Lead sponsor
International Biophysics Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 4, 2026, 1:02 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound

NCT03829618
View directory record Official record
Conditions
Bronchiectasis Adult, Mediastinal Lymphadenopathy, Pneumonia, Chest--Diseases, Infiltrates, Bronchopulmonary Disease, Cancer, Lung
Interventions
Topical lidocaine, Nebuliser solution, Nebuliser Suspension
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 4, 2026, 1:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls

NCT03125174
View directory record Official record
Conditions
Bronchiectasis Adult
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 4, 2026, 1:02 PM EDT
Completed Phase 1 Interventional

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

NCT01113034
View directory record Official record
Conditions
Asthma, Bronchiectasis
Interventions
DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 4, 2026, 1:02 PM EDT